Basic Information
HyperRHO S/D Injection
INJECTION
Regulatory Information
SIN09660P
March 3, 1998
Prescription Only
Therapeutic
INTRAMUSCULAR
August 10, 2023
June 3, 2025
XJ06BB01
Company Information
Active Ingredients
Strength: at least 1500 IU/dose
Detailed Information
Contraindications
**CONTRAINDICATIONS** None known.
Indication Information
**INDICATIONS AND USAGE** **Pregnancy and Other Obstetric Conditions** Hyper **RHO** S/D Full Dose is recommended for the prevention of Rh hemolytic disease of the newborn by its administration to the Rho(D) negative mother within 72 hours after birth of an Rho(D) positive infant,(12) providing the following criteria are met: 1. The mother must be Rho(D) negative and must not already be sensitized to the Rho(D) factor. 2. Her child must be Rho(D) positive, and should have a negative direct antiglobulin test (see PRECAUTIONS – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). If Hyper **RHO** S/D Full Dose is administered antepartum, it is essential that the mother receive another dose of Hyper **RHO** S/D Full Dose after delivery of an Rho(D) positive infant. If the father can be determined to be Rho(D) negative, Hyper **RHO** S/D Full Dose need not be given. Hyper **RHO** S/D Full Dose should be administered within 72 hours to all nonimmunized Rho(D) negative women who have undergone spontaneous or induced abortion, following ruptured tubal pregnancy, amniocentesis or abdominal trauma unless the blood group of the fetus or the father is known to be Rho(D) negative.(7,8) If the fetal blood group cannot be determined, one must assume that it is Rho(D) positive,(2) and Hyper **RHO** S/D Full Dose should be administered to the mother. **Transfusion** Hyper **RHO** S/D Full Dose may be used to prevent isoimmunization in Rho(D) negative individuals who have been transfused with Rho(D) positive red blood cells or blood components containing red blood cells.(5,13) * * * **REFERENCES** 1. Rho(D) immune globulin (human). _Med Lett Drugs Ther_ 16(1):3–4, 1974. 2. Pollack W, Ascari WQ, Crispen JF, et al: Studies on Rh prophylaxis. II. Rh immune prophylaxis after transfusion with Rh-positive blood. _Transfusion_ 11(6):340–4, 1971. 3. The selective use of Rho(D) immune globulin (RhIG). _ACOG Tech Bull_ 61, 1981. 4. Current uses of Rho immune globulin and detection of antibodies. _ACOG Tech Bull_ 35, 1976. 5. Ascari WQ, Allen AE, Baker WJ, et al: Rho(D) immune globulin (human): evaluation in women at risk of Rh immunization. _JAMA_ 205(1):1–4, 1968. 6. Prevention of Rh sensitization. _WHO Tech Rep Ser_ 468:25, 1971.